AI Article Synopsis
- Metastatic prostate cancer (PCa) is challenging to treat because it can develop resistance to therapies.
- Resistance may result from changes in the cancer cells or their environment, or from the emergence of a resistant subpopulation of cells.
- This case report provides evidence that a resistant subpopulation of cancer cells, which existed before treatment, can lead to therapy resistance and negatively impact patient survival.
Article Abstract
Metastatic prostate cancer (PCa) is not curable due to its ability to acquire therapy resistance. Theoretically, acquired therapy resistance can be driven by changes to previously sensitive cancer cells or their environment and/or by outgrowth of a subpopulation of cancer cells with primary resistance. Direct demonstration of the latter mechanism in patients with PCa is lacking. Here we present a case report as proof-of-principle that outgrowth of a subpopulation of cancer cells lacking the genomic target and present prior to therapy initiation can drive acquired resistance to targeted therapy and threaten survival in patients with PCa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612198 | PMC |
| http://dx.doi.org/10.1038/s41698-024-00773-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!